Evaluation of the combination of a biofilm-disrupting agent and negative pressure wound therapy: a case series

Thomas E Serena¹, Omar Jalodi¹, Laura Serena¹, Keyur Patel², Matthew Mynti³

¹ SerenaGroup Research Foundation, Cambridge, MA US.

JoWC, Vol. 3 0 , No. 1 , January 2021

Download Publication

Ready to see the difference?

MolecuLight Headquarters

425 University Avenue Suite 700 Toronto, ON M5G 1T6 Canada

US Address MolecuLight Corp. 2403 Sidney Street, Suite 286 Pittsburgh, PA 15203

T. 1-877-818-4360
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com

MolecuLight is SOC ll^®
Type l Accredited:

MolecuLight awarded
Premier’s Technology
Breakthrough Designation

MolecuLight i:X
is designated as a:

MolecuLight included
in ISWCAP Consensus
Guidelines:

MolecuLight is a proud
corporate member of:

Global

USA

©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.

Related Publications

Ready to see the difference?

MolecuLight Headquarters